COMMUNIQUÉS West-GlobeNewswire

Communiqué de presse : Sanofi fédère l'écosystème de santé pour accélérer le diagnostic des maladies rares en France : Biogen rejoint accelRare
03/06/2026
Sanofi fédère l’écosystème de santé pour accélérer le diagnostic des maladies rares en France : Biogen rejoint accelRare Paris, 3 juin 2026 - Sanofi annonce aujourd’hui l’arrivée de Biogen au sein d’ accelRare , outil [...]
ASCO 2026 | Updated Data from an Oral Presentation of InnoCare's Novel BCL2 Inhibitor Mesutoclax in MDS and AML Released
03/06/2026
BEIJING, June 02, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that updated data [...]
Zenas BioPharma Announces Data from the Registrational Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD), Simultaneously Presented at the EULAR 2026 Congress and Published in the New England Journal of Medicine
03/06/2026
- The INDIGO study met its primary and all key secondary endpoints with statistically significant results - - Obexelimab significantly lowered the total amount of glucocorticoid use and reduced glucocorticoid-related [...]
DBV Technologies annonce le screening du premier participant de l’étude clinique de phase 2 THRIVE pour le patch VIASKIN® Peanut chez les nourrissons âgés de 6 à 12 mois allergiques à l’arachide
03/06/2026
Châtillon, France, le 02 juin (22 :30 CEST) 2026 DBV Technologies annonce le screening du premier participant de l’étude clinique de phase 2 THRIVE pour le patch VIASKIN ® Peanut chez les nourrissons âgés de 6 à 12 mois [...]
DBV Technologies Announces First Participant Screened in THRIVE Phase 2 Study of the VIASKIN® Peanut Patch in Infants ages 6 through 12 Months with Peanut Allergy
03/06/2026
Châtillon, France, June 2, 2026 DBV Technologies Announces First Participant Screened in THRIVE Phase 2 Study of the VIASKIN ® Peanut Patch in Infants ages 6 through 12 Months with Peanut Allergy The study is evaluating [...]
Fortrea to Attend Jefferies Global Healthcare Conference
03/06/2026
DURHAM, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE), a leading global contract research organization (“CRO”), today announced that that CEO Anshul Thakral, CFO Jill McConnell, and SVP of Investor [...]
Nanobiotix fait le point sur sa tresorerie et son activite operationnelle pour le premier trimestre 2026
02/06/2026
Réalisation d’une augmentation de capital en mai 2026 pour un montant total d'environ 86,1 million d'euros bruts, incluant l'émission de bons de souscription préfinancés, pour accélérer le développement des autres [...]
PetMeds® Announces Fourth Quarter and Fiscal Year 2026 Financial Results
02/06/2026
DELRAY BEACH, Fla., June 02, 2026 (GLOBE NEWSWIRE) -- PetMed Express, Inc. dba PetMeds and parent company of PetCareRx (NASDAQ: PETS) today announced its financial results for its fourth quarter and fiscal year ended [...]
Crinetics and Leading Patient Groups Launch ‘Everyday Advocacy’ Initiative to Empower People Across Endocrine Disease Communities
02/06/2026
Everyday Advocacy provides people living with endocrine and endocrine-related conditions with education, support, and tools to facilitate more impactful healthcare team interactions Steering committee of five leading [...]
NRx Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
02/06/2026
WILMINGTON, Del., June 02, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx Pharmaceuticals” or the “Company”), a clinical-stage biopharmaceutical company, today announced that it intends to offer [...]
Crescent Biopharma to Present at June Investor Conferences
02/06/2026
WALTHAM, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies [...]
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/06/2026
NEW YORK and WALTHAM, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the [...]
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/06/2026
BOSTON, June 02, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced that [...]
Alvotech to present at upcoming investor conferences in June
02/06/2026
REYKJAVIK, ICELAND (June 2, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB) (the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today [...]
Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/06/2026
NEW HOPE, Pa., June 02, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through [...]
Onco360® Has Been Selected as a National Specialty Pharmacy Provider for IMKELDI® (imatinib) Oral Solution
02/06/2026
LOUISVILLE, KY, June 02, 2026 (GLOBE NEWSWIRE) -- Onco360 ® , the nation’s leading independent Specialty Pharmacy, has been selected as a pharmacy partner by Shorla Oncology for IMKELDI ® (imatinib) Oral Solution, [...]
vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
02/06/2026
HIGH POINT, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin , a novel, potential first-in-class oral [...]
Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/06/2026
LA JOLLA, Calif., June 02, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that on June [...]
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
02/06/2026
SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)- [...]

Pages